奥沙利铂联合氟尿嘧啶治疗老年晚期胃癌患者的临床疗效及不良反应

Clinical efficacy and adverse reaction of oxaliplatin combined with fluorouracil in the treatment of elderly patients with advanced gastric cancer

目的探讨奥沙利铂联合氟尿嘧啶治疗老年晚期胃癌患者的临床疗效及不良反应。方法根据治疗方式的不同将120例老年晚期胃癌患者分为对照组(n=60,伊立替康联合氟尿嘧啶治疗)和观察组(n=60,奥沙利铂联合氟尿嘧啶治疗)。比较两组患者的临床疗效、疾病进展时间、不良反应发生情况及生活质量[欧洲癌症研究与治疗组织生命质量测定量表(EORTC QLQ-C30)]。结果两组患者的客观缓解率、疾病控制率及疾病进展时间比较,差异均无统计学意义(P﹥0.05)。观察组患者白细胞减少、腹泻及周围神经病变发生率均低于对照组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者EORTC QLQ-C30各维度评分均高于本组治疗前,观察组患者认知功能、角色功能、社会功能评分均高于对照组,差异均有统计学意义(P﹤0.05)。结论奥沙利铂联合氟尿嘧啶治疗老年晚期胃癌患者能够获得与伊立替康联合氟尿嘧啶较为相似的临床疗效,但前者的安全性更高,且可提高患者的生活质量,值得临床推广。

Objective To investigate the clinical efficacy and adverse reaction of oxaliplatin combined with fluorouracil in the treatment of elderly patients with advanced gastric cancer.Method A total of 120 elderly patients with advanced gastric cancer were divided into control group(n=60,treated with irinotecan combined with fluorouracil)and observation group(n=60,treated with oxaliplatin combined with fluorouracil)according to different treatment methods.The clinical efficacy,disease progression time,adverse reaction,and quality of life[European Organization for Research and Treatment of Cancer quality of life questionnaire core 30(EORTC QLQ-C30)]were compared between the two groups.Result There were no significant differences in the objective response rate,disease control rate and disease progression time between the two groups(P>0.05).The incidence rates of leukopenia,diarrhea and peripheral neuropathy in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the scores of each dimension of EORTC QLQ-C30 in the two groups were higher than those before the treatment,the cognitive function,role function,and social function scores in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).Conclusion Oxaliplatin combined with fluorouracil could achieve comparable clinical efficacy to that of irinotecan plus fluorouracil in the treatment of elderly patients with advanced gastric cancer.However,the former regimen is worthy of clinical promotion owing to its high safety and improvement of patients’quality of life.